VX-522 was the first program in Moderna’s inhaled pulmonary therapeutics modality, and was never joined by any other candidates. (iStock/Getty Images Plus) After pausing a trial for a ...

Maddy Buxton, Culture & Trends manager at YouTube, discusses how creators and digital animation on the platform are global, fan-driven, popular among young adults, and driving innovation and ...

Assassin's Creed Unity, previously known as Assassin's Creed 5, is the next installment of the Assassin's Creed franchise. Unity will be released on PC, Xbox One and PlayStation 4. Assassin's Creed ...

Vertex's chief executive, Reshma Kewalramani. Vertex Pharma's bid to expand beyond its cystic fibrosis franchise has taken a big step forward, thanks to positive late-stage clinical data for ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...

Now, here's the reason I would buy and hold Vertex for the long term. It might surprise you when I say it doesn't have to do with the company's work beyond CF. Instead, I would hold onto this company ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Vertex executives warned that Casgevy, its ...

Vertex Pharmaceuticals' strategy is to develop medicines in areas with high unmet needs. The company has dominated the market for cystic fibrosis (CF) -- a rare disease that affects internal organs -- ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...